ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.
You are browsing the archive for Fidelity Biosciences - peHUB.
Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.
AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE [...]
Liazon, a private health benefits exchange, has closed $18.2 million in new funding to expand nationwide and develop new products. Bessemer Venture Partners and Fidelity Biosciences led the round with follow-on funding from existing investors Bain Capital Ventures and Rand Capital, SBIC. Founded in 2007, Liazon has offices in Buffalo, N.Y., New York City and [...]
Lately, there’s been a whole lot of bemoaning of this and that to explain why VCs are abandoning the biotech and device space and why strategics are slowing early-stage funding. Lawmakers and regulators have made it too tough to IPO. Lawmakers and regulators have made it too tough to get anything approved at the FDA. [...]
Allergan is buying privately held dermatology company Vicept Therapeutics. Formed in 2009, Vicept is backed by investors including Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Under the terms of the acquisition, which is expected to close during the third quarter, Allergan will pay $75 million in cash up-front, as well as up to $200 million in payments tied to specific milestones.
Globespan Capital Partners CFO Mary Bevelock Pendergast has left the venture capital firm to take the same role at Fidelity Biosciences, peHUB has learned.
ED NOTE: Nope, now it’s down.
Judging by Globespan’s description of her, Pendergast will leave a void behind in her wake. She managed all finance and administrative functions of the firm…
One-year-old start-up Ultragenyx Pharmaceutical Inc. has closed on a whopping $45 million Series A round co-led by TPG Biotech and Fidelity Biosciences. Other investors include HealthCap and Pappas Ventures. The money will help Novato, Calif.-based Ultragenyx continue development of its rare disease therapeutics. As a result of the round, Eran Nadav of TPG Biotech; Ben Auspitz of Fidelity Biosciences; and Mårten Steen of HealthCap will join the company’s board.